scholarly journals Allogeneic Bone Marrow–Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease

2021 ◽  
Author(s):  
Mya Schiess ◽  
Jessika Suescun ◽  
Marie‐Francoise Doursout ◽  
Christopher Adams ◽  
Charles Green ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Bone Marrow ◽  
Parkinson's Disease ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Idiopathic Parkinson’S Disease ◽  
Idiopathic Parkinson's Disease

scholarly journals Human Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Cerebellar Ataxia: A Case Report

Medicina ◽  
2021 ◽  
Vol 57 (4) ◽  
pp. 334
Author(s):  
Pan-Woo Ko ◽  
Sangmin Park ◽  
Kyunghun Kang ◽  
Yong-Hyun Lim ◽  
Sang Ryong Kim ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Cerebellar Ataxia ◽  
Stem Cell Therapy ◽  
Cerebellar Atrophy ◽  
Brain Magnetic Resonance Imaging ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone

To date, there is no curable treatment option for non-hereditary degenerative cerebellar ataxia. Here we report the case of a patient with sporadic adult-onset ataxia (SAOA) who underwent allogeneic bone marrow-derived mesenchymal stem cell (MSC) therapy via the intrathecal route. A 60-year-old male patient visited our clinic complaining of progressive gait disturbance that commenced two years ago. Upon neurologic examination, the patient exhibited limb dysmetria and gait ataxia. Brain magnetic resonance imaging (MRI) revealed cerebellar atrophy whereas the autonomic function test was normal. The patient was diagnosed with SAOA. The medications that were initially prescribed had no significant effects on the course of this disease and the symptoms deteriorated progressively. At the age of 64, the patient was treated with allogeneic bone marrow-derived MSC therapy. The subsequent K-SARA (Korean version of the Scale for the Assessment and Rating of Ataxia) scores demonstrated a distinct improvement up until 10 months post-administration. No adverse events were reported. The improved post-treatment K-SARA scores may suggest that the MSC therapy can have a neuroprotective effect and that stem cell therapy may serve as a potential therapeutic option for degenerative cerebellar ataxia.

Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease

2010 ◽  
Vol 155 (2) ◽  
pp. 62-70 ◽  
Author(s):  
Neelam K. Venkataramana ◽  
Satish K.V. Kumar ◽  
Sudheer Balaraju ◽  
Radhika Chemmangattu Radhakrishnan ◽  
Abhilash Bansal ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Bone Marrow ◽  
Parkinson's Disease ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Bone Marrow ◽  
Mesenchymal Stem Cell Transplantation ◽  
Autologous Bone
Sign in / Sign up

Export Citation Format

Share Document